Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer.
10.3802/jgo.2012.23.4.226
- Author:
Jeong Yeol PARK
1
;
Dae Yeon KIM
;
Jong Hyeok KIM
;
Yong Man KIM
;
Young Tak KIM
;
Young Seok KIM
;
Ha Jeong KIM
;
Jeong Won LEE
;
Byoung Gie KIM
;
Duk Soo BAE
;
Seung Jae HUH
;
Joo Hyun NAM
Author Information
1. Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jhnam@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Bulky early-stage cervical cancer;
Chemoradiation therapy;
Radical hysterectomy;
Stage IB2;
Stage IIA2
- MeSH:
Disease-Free Survival;
Follow-Up Studies;
Humans;
Hysterectomy;
Magnetic Resonance Spectroscopy;
Multivariate Analysis;
Recurrence;
Retrospective Studies;
Tertiary Care Centers;
Treatment Outcome;
Uterine Cervical Neoplasms
- From:Journal of Gynecologic Oncology
2012;23(4):226-234
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To compare survival outcomes and treatment-related morbidities between radical hysterectomy (RH) and primary chemoradiation therapy (CRT) in patients with bulky early-stage cervical cancer. METHODS: We selected 215 patients with stage IB2 and IIA2 cervical cancer (tumor diameter > 4 cm on magnetic resonance imaging) who underwent RH followed by tailored adjuvant therapy (n=147) or primary CRT (n=68) at two tertiary referral centers between 2001 and 2010. RESULTS: About twenty nine percent of patients were cured by RH alone and these patients experienced the best survival outcomes with the lowest morbidity rates. After the median follow-up times of 40 months, 27 RH (18.4%) and 20 CRT (29.4%) patients had recurrence (p=0.068) and 23 (15.6%) and 17 (25%) patients died of disease (p=0.101). The 5-year progression-free survival were 77% and 66% (p=0.047), and the 5-year overall survival were 78% and 67% (p=0.048) after RH and primary CRT, respectively. In multivariate analysis, patients who received primary CRT was at higher risk for tumor recurrence (odds ratio [OR], 2.26; 95% confidence interval [CI], 1.24 to 4.14; p=0.008) and death (OR, 3.02; 95% CI, 1.53 to 5.98; p=0.001) than those who received RH. Grade 3-4, early (17% vs. 30.9%, p=0.021) and late (1.4% vs. 8.8%, p=0.007) complications were significantly less frequent after RH than primary CRT. CONCLUSION: Thirty percent of patients were cured by RH alone. A treatment outcome was better in this retrospective study in terms of morbidity and survival. Randomized trials are needed to confirm this result.
